ALT, AST, and tBil measurements were available in 1,062, 1,057, and 1,005 participants (98.5%, 98.1%, and 93.2% of all STRONG-HF participants, respectively), and the median (Q1-Q3) concentrations were 21 (15-32) U/L, 23 (17-32) U/L, and 14 (10-21) umol/L, respectively, at baseline. The gene discussed is GPT; the disease is hydrops fetalis.